Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 cemiplimab monotherapy in advanced basal cell carcinoma after prior hedgehog pathway inhibitor therapy
2016-003122-16Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cemiplimab in basal cell carcinoma (BCC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Overall response rate. Started Jun 2017; status: completed.
02
Drugs
cemiplimab
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2016-003122-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003122-16.